American College of Medical Genetics and Genomics (ACMG)

acmg.net

The American College of Medical Genetics and Genomics (ACMG) provides education, resources and a voice for the medical genetics and genomics profession. To make genetic services available to and improve the health of the public, the ACMG promotes the development and implementation of methods to diagnose, treat and prevent genetic diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

BEIGENE ANNOUNCES APPROVAL FOR BRUKINSA (ZANUBRUTINIB) BY SWISSMEDIC FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖMS MACROGLOBULINEMIA

BeiGene | February 18, 2022

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orphan drug status. ...

Read More

Cell and Gene Therapy

AGEX THERAPEUTICS RECEIVES STOCK EXCHANGE DEFICIENCY LETTER

AgeX Therapeutics | November 24, 2021

news image

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses d...

Read More

Cell and Gene Therapy

MERCK ENTERS INTO OUT-LICENSING AGREEMENT WITH BIOTECHNOLOGY COMPANY VERA THERAPEUTICS

Merck | November 11, 2020

news image

Merck, a leading science and technology company, today announced that it, through its subsidiary Ares Trading S.A., has entered into an out-licensing agreement with biotechnology company Vera Therapeutics, South San Francisco, USA, for the further development of investigational therapy atacicept. Vera Therapeutics will first prioritize to take atacicept into a Phase IIb study in IgA nephropathy (IgAN), an autoimmune kidney disease also known as "Berger's disease". "The positiv...

Read More

MedTech

ORACLE AND OXFORD NANOPORE TEAM UP TO IMPROVE HEALTHCARE AND SPEED DISCOVERY OF NEW MEDICAL BREAKTHROUGHS

Oracle | September 16, 2021

news image

Advances in DNA/RNA sequencing promise to revolutionize how medical communities identify, detect, and treat diseases and manage public health threats. To make this technology more accessible and increase its impact, Oracle has teamed up with Oxford Nanopore Technologies, the company behind a new generation of high-performance, rapid, scalable, and accessible sequencing technology. Oracle and Oxford Nanopore have recently begun a collaboration to jointly explore several potential n...

Read More
news image

Industrial Impact

BEIGENE ANNOUNCES APPROVAL FOR BRUKINSA (ZANUBRUTINIB) BY SWISSMEDIC FOR TREATMENT OF ADULT PATIENTS WITH WALDENSTRÖMS MACROGLOBULINEMIA

BeiGene | February 18, 2022

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that BeiGene’s BTK inhibitor BRUKINSA received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia who have received at least one prior line of therapy, or for treatment-naïve patients who are not suited for standard chemo-immunotherapy. BRUKINSA had previously been granted orphan drug status. ...

Read More
news image

Cell and Gene Therapy

AGEX THERAPEUTICS RECEIVES STOCK EXCHANGE DEFICIENCY LETTER

AgeX Therapeutics | November 24, 2021

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses d...

Read More
news image

Cell and Gene Therapy

MERCK ENTERS INTO OUT-LICENSING AGREEMENT WITH BIOTECHNOLOGY COMPANY VERA THERAPEUTICS

Merck | November 11, 2020

Merck, a leading science and technology company, today announced that it, through its subsidiary Ares Trading S.A., has entered into an out-licensing agreement with biotechnology company Vera Therapeutics, South San Francisco, USA, for the further development of investigational therapy atacicept. Vera Therapeutics will first prioritize to take atacicept into a Phase IIb study in IgA nephropathy (IgAN), an autoimmune kidney disease also known as "Berger's disease". "The positiv...

Read More
news image

MedTech

ORACLE AND OXFORD NANOPORE TEAM UP TO IMPROVE HEALTHCARE AND SPEED DISCOVERY OF NEW MEDICAL BREAKTHROUGHS

Oracle | September 16, 2021

Advances in DNA/RNA sequencing promise to revolutionize how medical communities identify, detect, and treat diseases and manage public health threats. To make this technology more accessible and increase its impact, Oracle has teamed up with Oxford Nanopore Technologies, the company behind a new generation of high-performance, rapid, scalable, and accessible sequencing technology. Oracle and Oxford Nanopore have recently begun a collaboration to jointly explore several potential n...

Read More